Pfizer Inc. (BVMF:PFIZ34)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep 28, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	2011 - 2020
Primary Care Revenue	27.79B	30.14B	Log In	Log In	Log In	Upgrade
Specialty Care Revenue	17.21B	16.65B	Log In	Log In	Log In	Upgrade
Oncology Revenue	16.46B	15.61B	Log In	Log In	Log In	Upgrade
Global Pharmaceuticals Business (Biopharma) Revenue	61.47B	62.40B	Log In	Log In	Log In	Upgrade
Business Innovation (Pfizer CentreOne) Revenue	1.26B	1.15B	Log In	Log In	Log In	Upgrade
Revenue (Other)	62.00M	81.00M	Log In	Log In	Log In	Upgrade
Revenue (Total)	62.79B	63.63B	Log In	Log In	Log In	Upgrade

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep 28, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	2011 - 2020
United States Revenue	37.18B	38.69B	Log In	Log In	Log In	Upgrade
Developed Markets Revenue	16.55B	16.06B	Log In	Log In	Log In	Upgrade
Emerging Markets Revenue (Post-FY2023 Reporting)	9.06B	8.88B	Log In	Log In	Log In	Upgrade
Revenue (Other)	1.00M	-	Log In	Log In	Log In	Upgrade
Revenue (Total)	62.79B	63.63B	Log In	Log In	Log In	Upgrade

Revenue by Geography 2

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep 28, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	2011 - 2020
United States Revenue	37.18B	38.69B	Log In	Log In	Log In	Upgrade
Revenue (Total)	62.79B	63.63B	Log In	Log In	Log In	Upgrade

Revenue by Geography 3

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep 28, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	2011 - 2020
United States Revenue	37.18B	38.69B	Log In	Log In	Log In	Upgrade
Developed Europe Revenue	-	-	Log In	Log In	Log In	Upgrade
Developed Rest of World Revenue	-	-	Log In	Log In	Log In	Upgrade
Emerging Markets Revenue	-	-	Log In	Log In	Log In	Upgrade
International Revenue	25.61B	24.94B	Log In	Log In	Log In	Upgrade
Revenue (Total)	62.79B	63.63B	Log In	Log In	Log In	Upgrade

EBT

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep 28, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	2011 - 2020
Global Pharmaceuticals Business (Biopharma) Earnings	28.80B	28.14B	Log In	Log In	Log In	Upgrade
Other Business Activities Earnings	-8.17B	-7.38B	Log In	Log In	Log In	Upgrade

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep 28, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	2011 - 2020
Comirnaty Direct Sales and Alliance Revenue	5.48B	5.35B	Log In	Log In	Log In	Upgrade
Eliquis Alliance Revenue and Direct Sales	7.77B	7.37B	Log In	Log In	Log In	Upgrade
Prevnar Revenue	-	-	Log In	Log In	Log In	Upgrade
Paxlovid Revenue	2.87B	5.72B	Log In	Log In	Log In	Upgrade
Prevnar Family Revenue	6.34B	6.41B	Log In	Log In	Log In	Upgrade
Nurtec ODT/Vydura Revenue	1.41B	1.26B	Log In	Log In	Log In	Upgrade
Abrysvo Revenue	751.00M	755.00M	Log In	Log In	Log In	Upgrade
Vyndaqel Family Revenue	6.24B	5.45B	Log In	Log In	Log In	Upgrade
Xeljanz Revenue	1.11B	1.17B	Log In	Log In	Log In	Upgrade
Ibrance Revenue	4.18B	4.37B	Log In	Log In	Log In	Upgrade
Vaccines Revenue	-	-	Log In	Log In	Log In	Upgrade
Internal Medicine Revenue	-	-	Log In	Log In	Log In	Upgrade
Hospital Revenue	-	-	Log In	Log In	Log In	Upgrade
Inflammation & Immunology Revenue	-	-	Log In	Log In	Log In	Upgrade
Rare Disease Revenue	-	-	Log In	Log In	Log In	Upgrade

Updated Sep 28, 2025. Data Source: Fiscal.ai.